Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA
Post by: Colleen Parr Dekker
Guelph, ON., Oct. 15, 2014—The Honorable Ed Holder, Minister of State (Science and Technology), has announced a three-year project collaboration between Elanco Animal Health and Concordia University to develop new enzyme combinations for Canadian pork and poultry producers. The goal of the project is to create commercial enzyme products for pork and poultry feed that significantly improve feed conversion, thus improving producer profit margins.
The project will be funded by Elanco ($3M), the Ministère de l’Économie, de l’Innovation et des Exportations du Québec through Genome Quebec ($1M) and the government of Canada through Genome Canada ($2M).
“Today, up to 25% of the components in pork and poultry feed remain unused because the animals lack the enzymes required for digestion,” said Allan Boonstra, director of Elanco Animal Health. “Feed costs make up about 70% of the cost of producing pork and poultry, so this project has the potential to generate significant value for producers.”
Dr. Adrian Tsang from Concordia and Dr. Paul Matzat from Elanco will lead the project. The work will involve screening proprietary enzymes for digestibility of common ingredients found in Canadian pork and poultry feed. Commercial products suited for the Canadian feed market are expected to result in significant improvements in feed conversion.
“Upon successful completion, this project is expected to provide benefits in the form of lower production costs, increased global competitiveness for swine and poultry producers, and more competitively priced meat and eggs,” said Marc Lepage, CEO of Genome Quebec. “In terms of feed production, we can also expect reduced land use and increased use of Canadian grains such as canola.”
Dr. Pierre Meulien, President and CEO of Genome Canada, added, "This project is one of several academic-industry partnership projects receiving funding under Genome Canada's new Genomic Applications Partnership Program, which was designed to facilitate industry engagement in Canadian R&D. Companies such as Elanco are seizing the opportunity to leverage Canada's strong genomics science and technology capacity for the benefit of their business and the Canadian economy."
The project complements Elanco’s mission to help the global food chain deliver a safe, affordable and sufficient food supply. Boonstra continued, “We believe innovation in sustainable food production is one of the most important mechanisms to feeding a growing global population. Elanco anticipates this project will lead to expanded research and development in Quebec and throughout Canada.”
Elanco is a global innovation-driven company that develops and markets products and services to improve animal health and food-animal production in more than 75 countries. Elanco employs more than 3,000 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at www.elanco.ca.
CONTACT:Marta Haley, Elanco Canada — firstname.lastname@example.org or +1-613-220 6770.
Elanco© and the diagonal bar are trademarks owned or licenced by Eli Lilly and Company, its subsidiaries or affiliates. Used under licence by ELANCO/Division of Eli Lilly Canada Inc. All other trademarks are the property of their respective owners.
© 2014 Elanco Animal Health. All rights reserved. CABRDMIS00010
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.